← Eichor
Study identifier: NCT06647953 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Condition: Pleuropulmonary Blastoma  ·  Sponsor: Children's Oncology Group

PhasePhase 3
Planned participants110
Who can joinAll sexes, N/A to 21 Years
Healthy volunteersNo

About this study

This phase III trial tests how well surgery plus chemotherapy compared to surgery alone works in treating patients with type I pleuropulmonary blastoma (PPB), and tests how well surgery plus standard chemotherapy with the addition of topotecan works compared to surgery plus standard chemotherapy alone in treating patients with type II and III PPB. Historically, most children with type I PPB had surgery and approximately 40% of children with type I PPB received chemotherapy following their surgery, usually for 22-42 weeks. There has not been a consistent standard for which children with type I PPB receive chemotherapy after surgery. For patients whose tumor has been removed completely with surgery, observation without chemotherapy may work as well as giving chemotherapy after surgery in preventing a return of the PPB tumor. The standard chemotherapy for patients with types II or III PPB in the United States is four cycles of IVADo (ifosfamide, vincristine, dactinomycin, and doxorubicin) followed by 8 cycles of IVA (ifosfamide, vincristine and dactinomycin). Ifosfamide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. Vincristine is in a class of medications called vinca alkaloids. It works by stopping tumor cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's deoxyr…

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (82)

Children's Hospital of AlabamaBirmingham, Alabama, United StatesRecruiting
Phoenix Childrens HospitalPhoenix, Arizona, United StatesRecruiting
Arkansas Children's HospitalLittle Rock, Arkansas, United StatesRecruiting
Loma Linda University Medical CenterLoma Linda, California, United StatesRecruiting
Children's Hospital Los AngelesLos Angeles, California, United StatesRecruiting
Valley Children's HospitalMadera, California, United StatesRecruiting
UCSF Benioff Children's Hospital OaklandOakland, California, United StatesRecruiting
Kaiser Permanente-OaklandOakland, California, United StatesRecruiting
UCSF Medical Center-Mission BaySan Francisco, California, United StatesRecruiting
Children's Hospital ColoradoAurora, Colorado, United StatesRecruiting
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical CenterDenver, Colorado, United StatesRecruiting
Alfred I duPont Hospital for ChildrenWilmington, Delaware, United StatesRecruiting

+ 70 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06647953